Post-traumatic Stress Disorder in Middle Age and Beyond
- PMID: 33766192
- DOI: 10.4140/TCP.n.2021.191
Post-traumatic Stress Disorder in Middle Age and Beyond
Abstract
Objective: To review the clinical manifestations and treatment of post-traumatic stress disorder (PTSD) in adults and older people.
Data sources: Articles indexed in PubMed, Embase, psychology databases, and the Cochrane library over the past 10 years using the key words "post-traumatic stress disorder," "stress disorders," and "post-traumatic stress disorder and treatment."
Study selection and data extraction: Sixty-seven publications were reviewed and criteria supporting the primary objective were used to identify useful resources.
Data synthesis: The literature included practice guidelines; review articles; original research articles; and product prescribing information for the clinical manifestations, diagnosis, and treatment of PTSD.
Conclusion: Psychotherapy is the first-line therapy for PTSD. Pharmacologic therapy is recommended, as second-line therapy, for adults living with PTSD who do not have access to psychotherapy or refuse psychotherapy. Pharmacologic therapy may also be considered in cases of partial, or no, response to psychotherapy. Current guidelines recommend prescribing one of 3 selective serotonin-reuptake inhibitors, either fluoxetine, paroxetine, or sertraline, or prescribing the serotonin norepinephrine reuptake inhibitor venlafaxine, for adult patients who do not have access to psychotherapy or prefer not to use psychotherapy. Unfortunately, these recommended medications have additional cautions for use in older people so may not be appropriate for many older people living with PTSD. Therapy for older people should be tailored to patient-specific symptoms, with careful consideration of the potential benefits and risks of the therapy and coexisting medical conditions of each patient.
Similar articles
-
Patient journey before and after a formal post-traumatic stress disorder diagnosis in adults in the United States - a retrospective claims study.Curr Med Res Opin. 2023 Nov;39(11):1523-1532. doi: 10.1080/03007995.2023.2269839. Epub 2023 Oct 17. Curr Med Res Opin. 2023. PMID: 37817472
-
Posttraumatic Stress Disorder: Evaluation and Treatment.Am Fam Physician. 2023 Mar;107(3):273-281. Am Fam Physician. 2023. PMID: 36920821
-
Patient and Clinical Factors Associated With Response to Medications for Posttraumatic Stress Disorder.J Clin Psychiatry. 2021 Oct 5;82(6):21m13913. doi: 10.4088/JCP.21m13913. J Clin Psychiatry. 2021. PMID: 34610227
-
Perinatal Posttraumatic Stress Disorder: A Review of Risk Factors, Diagnosis, and Treatment.Obstet Gynecol Surv. 2019 Jun;74(6):369-376. doi: 10.1097/OGX.0000000000000680. Obstet Gynecol Surv. 2019. PMID: 31216046 Review.
-
SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations.Drugs. 2004;64(4):383-404. doi: 10.2165/00003495-200464040-00004. Drugs. 2004. PMID: 14969574 Review.
Cited by
-
Correlation between 5-HTTLPR gene polymorphism and cognitive function of traumatic stress in Chinese Han children.Transl Pediatr. 2022 Jul;11(7):1251-1260. doi: 10.21037/tp-22-289. Transl Pediatr. 2022. PMID: 35958016 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous